A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype
Condition: Beta-Thalassemia
MeSH terms: Thalassemia; beta-Thalassemia
Intervention: LentiGlobin BB305 Drug Product
Intervention description: LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 24.0
Sex: All
Minimum age: 0 Years
Maximum age: 50 Years
Healthy volunteers: No

Summary:

      This is a single-arm, multi-site, single-dose, Phase 3 study in 23 participants less than or
      equal to (<=) 50 years of age with transfusion-dependent β-thalassemia (TDT), also known as
      β-thalassemia major, who do not have a β0 mutation at both alleles of the hemoglobin β (HBB)
      gene. The study will evaluate the efficacy and safety of autologous hematopoietic stem cell
      transplantation (HSCT) using LentiGlobin BB305 Drug Product.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Participants <= 50 years of age at the time of consent or assent (as applicable), and
             able to provide written consent (adults, or legal guardians, as applicable) or assent
             (adolescents or children). Provided that the Data Monitoring Committee (DMC) has
             approved enrolling participants younger than 5 years of age, participants younger than
             5 years of age may be enrolled if they weigh a minimum of 6 kilograms (kg) and are
             reasonably anticipated to be able to provide at least the minimum number of cells
             required to initiate the manufacturing process.

          -  Diagnosis of TDT with a history of at least 100 milliliter per kilogram per year
             (mL/kg/year) of pRBCs in the 2 years preceding enrollment (all participants), or be
             managed under standard thalassemia guidelines with >= 8 transfusions of pRBCs per year
             in the 2 years preceding enrollment (participants >= 12 years).

          -  Clinically stable and eligible to undergo (HSCT).

          -  Treated and followed for at least the past 2 years in a specialized center that
             maintained detailed medical records, including transfusion history.

        Exclusion Criteria:

          -  Presence of a mutation characterized as β0 mutation at both alleles of the β-globin
             gene HBB.

          -  Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 and HIV-2),
             hepatitis B virus (HBV), or hepatitis C (HCV).

          -  A white blood cell (WBC) count less than (<) 3×10^9/Liter (L), and/or platelet count <
             100×10^9/L not related to hypersplenism.

          -  Uncorrected bleeding disorder.

          -  Any prior or current malignancy.

          -  Immediate family member with a known Familial Cancer Syndrome.

          -  Prior HSCT.

          -  Advanced liver disease.

          -  A cardiac T2* < 10 ms by MRI.

          -  Any other evidence of severe iron overload that, in the Investigator's opinion,
             warrants exclusion.

          -  Participation in another clinical study with an investigational drug within 30 days of
             Screening.

          -  Any other condition that would render the participant ineligible for HSCT, as
             determined by the attending transplant physician or investigator.

          -  Prior receipt of gene therapy.

          -  Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception
             for fertile participant.

          -  A known and available Human leukocyte antigen (HLA) matched family donor.

          -  Any contraindications to the use of granulocyte colony stimulating factor (G-CSF) and
             plerixafor during the mobilization of hematopoietic stem cells and any
             contraindications to the use of busulfan and any other medicinal products required
             during the myeloablative conditioning, including hypersensitivity to the active
             substances or to any of the excipients.